The labdane diterpene sclareol (labd-14-ene-8, 13-diol) induces apoptosis in human tumor cell lines and suppression of tumor growth in vivo via a p53-independent mechanism of action

Allen, 2004, Drug delivery systems: entering the mainstream, Science, 19, 1818, 10.1126/science.1095833 Balan, 2005, Induction of apoptosis in human colon cancer HCT116 cells treated with an extract of the plant product, Chios mastic gum, In Vivo, 19, 93 Balan, 2007, Antiproliferative activity and induction of apoptosis in human colon cancer cells treated in vitro with constituents of a product derived from Pistacia lentiscus L. var. chia, Phytomedicine, 4, 263, 10.1016/j.phymed.2006.03.009 Bartsch, 2005, Cell-specific targeting of lipid-based carriers for ODN and DNA, J. Liposome Res., 15, 59, 10.1081/LPR-200064961 Batist, 2001, Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer, J. Clin. Oncol., 19, 1444, 10.1200/JCO.2001.19.5.1444 Boyd, 1995, Some practical considerations and applications of the National Cancer Institute in vitro anticancer drug discovery screen, Drug Dev. Res., 34, 91, 10.1002/ddr.430340203 Brown, 2004, Apoptosis, p53, and tumor cell sensitivity to anticancer agents, Cancer Res., 59, 1391 Chen, 2004, Drug delivery across the blood–brain barrier, Curr. Drug Deliv., 1, 361, 10.2174/1567201043334542 Cimoli, 2004, Meta-analysis of the role of p53 status in isogenic systems tested for sensitivity to cytotoxic antineoplastic drugs, Biochim. Biophys. Acta, 1705, 103 Connoly, 1991 Connor, 1997, Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents, Cancer Res., 57, 4285 Crow, 2006, P53 apoptotic response to DNA damage on Bcl-2 but not Bax in head and neck squamous cell carcinoma cell lines, Head Neck, 28, 15, 10.1002/hed.20319 D'Incalci, 2005, Use of cancer chemopreventive phytochemicals as antineoplastic agents, Lancet Oncol., 6, 899, 10.1016/S1470-2045(05)70425-3 DeBonis, 2004, In vitro screening for inhibitors of the human mitotic kinesin Eg5 with antimitotic and antitumor activities, Mol. Cancer Ther., 3, 1079 Demetzos, 2001, Labdane-type diterpenes: chemistry and biological activity, 235, 10.1016/S1572-5995(01)80009-0 Dimas, 1998, Cytotoxic activity of labdane type diterpenes against human leukemic cell lines in vitro, Planta Med., 64, 208, 10.1055/s-2006-957410 Dimas, 1999, The effect of sclareol on growth and cell cycle progression of human leukemic cell lines, Leuk. Res., 23, 217, 10.1016/S0145-2126(98)00134-9 Dimas, 1999, Cytotoxic activity and antiproliferative effects of a new semi-synthetic derivative of ent-3 beta-hydroxy-13-epi-manoyl oxide on human leukemic cell lines, Anticancer. Res., 19, 4065 Dimas, 2001, Labdane type diterpenes down-regulate the expression of c-Myc protein but not of Bcl-2, in human leukemia T-cell lines undergoing apoptosis, Leuk. Res., 25, 449, 10.1016/S0145-2126(00)00150-8 Dimas, 2006, Labd-14-ene-8, 13-diol (sclareol) induces cell cycle arrest and apoptosis in human breast cancer cells and enhances the activity of anticancer drugs, Biomed. Pharmacother., 60, 127, 10.1016/j.biopha.2006.01.003 Dimas, 2007, Sclareol induces apoptosis in human HCT116 colon cancer cells in vitro and suppression of HCT116 tumor growth in immunodeficient mice, Apoptosis, 12, 685, 10.1007/s10495-006-0026-8 Gibson, 1985, Identification of specific DNA lesions induced by three classes of chloroethylating agents: chloroethylnitrosoureas, chloroethylmethanesulfonates and chloroethylimidazotetrazines, Pharmacol. Ther., 31, 153, 10.1016/0163-7258(85)90042-7 Han, 2002, Role of p21 in apoptosis and senescence of human colon cancer cells treated with camptothecin, J. Biol. Chem., 277, 17154, 10.1074/jbc.M112401200 Hatziantoniou, 2006, Cytotoxic and antitumor activity of liposome-incorporated sclareol against cancer cell lines and human colon cancer xenografts, Pharmacol. Res., 53, 80, 10.1016/j.phrs.2005.09.008 Hofler, 2006, Prediction of response to neoadjuvant chemotherapy in carcinoma of the upper gastrointestinal tract, Adv. Exp. Med. Biol., 587, 115, 10.1007/978-1-4020-5133-3_11 Hu, 2003, Differential susceptibility to 9-nitrocamptothecin (9-NC)-induced apoptosis in clones derived from a human ovarian cancer cell line, possible implications in the treatment of ovarian cancer patients with 9-NC, Anticancer Drugs, 14, 427, 10.1097/00001813-200307000-00007 Jackson, 1975, Aspects of the biochemical pharmacology of cytembena, Neoplasma, 22, 259 Jung, 1998, A concise synthesis and in vitro cytotoxicity of new labdane diterpenes, Bioorg. Med. Chem. Lett., 8, 3295, 10.1016/S0960-894X(98)00603-9 Kelley, 2005, Tumor response to neoadjuvant chemoradiation therapy for rectal adenocarcinoma is mediated by p53-dependent and caspase-8 dependent apoptotic pathways, Clin. Colorectal Cancer, 5, 114, 10.3816/CCC.2005.n.023 Krammer, 2004, Death receptors in chemotherapy and cancer, Oncogene, 23, 2950, 10.1038/sj.onc.1207558 Kshirsagar, 2005, Liposomal drug delivery system from laboratory to clinic, J. Postgrad. Med., 51, S5 Lee, 2005, Labdane diterpenes from Aster spathulifolius and their cytotoxic effects on human cancer cell lines, J. Nat. Prod., 68, 1471, 10.1021/np058044e Li, 1998, Cleavage of Bid by caspase-8 mediates the mitochondrial damage in the Fas pathway of apoptosis, Cell, 94, 491, 10.1016/S0092-8674(00)81590-1 Li, 2005, Labdane-type diterpenes as new cell cycle inhibitors and apoptosis inducers from Vitex trifolia L, J. Asian Nat. Prod. Res., 7, 95, 10.1080/10286020310001617165 Liebermann, 2007, P53-induced growth arrest versus apoptosis and its modulation by survival cytokines, Cell Cycle, 6, 166, 10.4161/cc.6.2.3789 Lockshin, 2004, Caspase-independent cell death?, Oncogene, 23, 2766, 10.1038/sj.onc.1207514 Lowe, 1994, P53 status and the efficacy of cancer therapy in vivo, Science, 266, 807, 10.1126/science.7973635 Luo, 1998, Bid, a Bcl-2-interacting protein mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors, Cell, 94, 481, 10.1016/S0092-8674(00)81589-5 Nishino, 2005, Cancer prevention by phytochemicals, Oncology, 69, 38, 10.1159/000086631 Oren, 1999, Introduction: p53 — the first twenty years, Cell. Mol. Life Sci., 55, 9, 10.1007/s000180050265 Paull, 1989, Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm, JNCI, 81, 1088, 10.1093/jnci/81.14.1088 Petitjean, 2007, Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database, Hum. Mutat., 28, 622, 10.1002/humu.20495 Plowman, 1997, Human tumor xenograft models in NCI drug development, 117 Ravi, 2000, Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1, Genes Dev., 14, 34, 10.1101/gad.14.1.34 Rozhin, 1983, Effects of 4-nitroestrone 3-methyl ether on dimethylbenz(a)anthracene-induced mammary tumors, Cancer Res., 43, 2611 Sellers, 1999, Apoptosis and cancer drug targeting, J. Clin. Invest., 104, 1655, 10.1172/JCI9053 Sengupta, 2005, p53: traffic cop at the crossroads of DNA repair and recombination, Nat. Rev. Mol. Cell Biol., 6, 44, 10.1038/nrm1546 Souza-Fagundes, 2003, Myriadenolide, a labdane diterpene isolated from Alomia myriadenia (asteraceae) induces depolarization of mitochondrial membranes and apoptosis associated with activation of caspases-8, -9, and -3 in Jurkat and THP-1 cells, Exp. Cell Res., 290, 420, 10.1016/S0014-4827(03)00350-1 Strasser, 2001, Apoptosis signaling, Annu. Rev. Biochem., 69, 217, 10.1146/annurev.biochem.69.1.217 Wallace, 2004, Inhibitors of polyamine metabolism: review article, Amino Acids, 26, 353, 10.1007/s00726-004-0092-6 Weinstein, 1997, An information intensive approach to the molecular pharmacology of cancer, Science, 275, 343, 10.1126/science.275.5298.343 Yuan, 1995, Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size, Cancer Res., 55, 3752 Zamboni, 2005, Liposomal, nanoparticle, and conjugated formulations of anticancer agents, Clin. Cancer Res., 11, 8230, 10.1158/1078-0432.CCR-05-1895